These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 24086072

  • 1. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.
    Choi CM, Kim MY, Lee JC, Kim HJ.
    Radiology; 2014 Feb; 270(2):574-82. PubMed ID: 24086072
    [Abstract] [Full Text] [Related]

  • 2. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM, Kim MY, Hwang HJ, Lee JB, Kim WS.
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [Abstract] [Full Text] [Related]

  • 3. Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
    Chang S, Hur J, Hong YJ, Lee HJ, Kim YJ, Han K, Choi BW.
    AJR Am J Roentgenol; 2018 Jan; 210(1):43-51. PubMed ID: 29091002
    [Abstract] [Full Text] [Related]

  • 4. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y, Ma Y, Li Y, Shen X, Yu Y, Pan Y, Zhang Y, Yu S, Zheng D, Zhao Y, Hu H, Sun Y, Zhang Y, Xiang J, Chen H.
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [Abstract] [Full Text] [Related]

  • 5. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM.
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [Abstract] [Full Text] [Related]

  • 6. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP.
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
    Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.
    PLoS One; 2017 Sep; 12(11):e0187500. PubMed ID: 29099855
    [Abstract] [Full Text] [Related]

  • 15. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 16. CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.
    Ozkan E, West A, Dedelow JA, Chu BF, Zhao W, Yildiz VO, Otterson GA, Shilo K, Ghosh S, King M, White RD, Erdal BS.
    AJR Am J Roentgenol; 2015 Nov; 205(5):1016-25. PubMed ID: 26496549
    [Abstract] [Full Text] [Related]

  • 17. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS.
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [Abstract] [Full Text] [Related]

  • 18. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, Lee KS.
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
    Peng M, Weng YM, Liu HL, Yang GF, Yao Y, Han G, Song QB.
    Biomed Res Int; 2018 May; 2018():7181368. PubMed ID: 29581983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.